What is maintenance therapy for Mantle Cell Lymphoma and when is it recommended

Maintenance Therapy for Mantle Cell Lymphoma

Maintenance therapy is a follow-up treatment given after your initial (induction) therapy to help keep the cancer in remission longer. Think of it as a "holding pattern" to prevent the lymphoma from coming back. Let me explain when and how it's used in mantle cell lymphoma (MCL).

What Maintenance Therapy Is

Maintenance therapy involves continuing lower-dose or less intensive treatment for an extended period—typically months to years—after you've completed your main cancer treatment. The goal is to maintain the remission (cancer-free state) you achieved with initial therapy.

When Maintenance Is Recommended

According to NCCN Guidelines for Mantle Cell Lymphoma, maintenance therapy recommendations depend on what initial treatment you received:

After Less Aggressive Induction Therapy:

• Rituximab maintenance is recommended for 2-3 years following RCHOP (a chemotherapy combination)
  • This is a Category 1 recommendation (highest level of evidence)
  • Rituximab is given every 8 weeks
  • This applies when you've achieved a complete response (CR) or partial response (PR)

After Aggressive Induction Therapy or HDT/ASCR:

• Covalent BTKi (Bruton's Tyrosine Kinase inhibitor) for a fixed duration of 2 years
  • Examples include ibrutinib, acalabrutinib, or zanubrutinib
  • PLUS rituximab every 8 weeks for 3 years
  • The TRIANGLE study showed that 2 years of ibrutinib maintenance after alternating RCHOP + ibrutinib/RDHA improved outcomes

Key Points About Your Specific Situation

Your oncologist will determine if maintenance therapy is right for you based on:

• Your initial response to treatment (complete vs. partial response)
• Which induction therapy you received
• Your overall health and ability to tolerate ongoing treatment
• Whether you have TP53 mutations (which may affect treatment decisions)

Questions to Ask Your Healthcare Team

1. Did I achieve a complete response or partial response to my initial treatment?
2. Based on my specific treatment, what maintenance therapy do you recommend?
3. How long will I need maintenance therapy, and what does the schedule look like?
4. What are the potential side effects of the maintenance therapy you're recommending?
5. How will we monitor whether the maintenance therapy is working?

Important Context

The NCCN Guidelines emphasize that maintenance therapy is an important part of the overall treatment plan for many MCL patients. However, the specific approach varies significantly based on your individual situation, your response to initial treatment, and your fitness for different types of therapy.

According to NCCN Guidelines, patients who achieve a very good partial response (VGPR) may be candidates for active surveillance instead of additional maintenance, while those with minimal partial response are considered to have refractory disease and need different approaches.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.